# Apollo Global Management Moat

Status: stale. Policy: company-analysis-1.

Apollo has a narrow moat supported by a substantial base of capital subject to withdrawal restrictions, integrated insurance investment services and an established investment track record. These advantages support persistent fee relationships, but do not establish broad pricing power or immunity from competition. Fee growth reflects assets, acquisitions and fee-basis changes; insurance funding costs show competitive pressure. Durability depends on investment performance, capital adequacy and continued investor demand.

## switching_costs

Withdrawal restrictions in indefinite-duration vehicles create current switching friction across a material capital base: perpetual capital represented $535.6 billion of $938.4 billion AUM at year-end 2025. Apollo also provides investment management and operational support to Athene, supporting embedded service relationships. Affiliated assets are not independent evidence of customer preference.

Durability: Multi-year investment horizons and contractual withdrawal limitations support persistence beyond a single fundraising cycle. Perpetual capital is neither irrevocable nor guaranteed to remain with Apollo.

Risks: Service agreements can terminate, withdrawals remain possible and some insurance products have no surrender charges. Poor investment results, weaker ratings or liquidity pressure could erode the capital base and future fundraising.

Invalidation: Sustained redemptions exceeding subscriptions, material termination of perpetual-vehicle mandates, or withdrawal-rule changes that materially shorten capital duration would undermine this advantage.

Competitors: Not established
## intangible_assets

Apollo's accumulated investment expertise and distribution relationships support fundraising and origination. Reported traditional private-equity returns, organic inflows and capital-solutions activity provide operating evidence beyond management's differentiation claims. They support a limited franchise advantage, without proving superior performance across the predominantly credit-oriented business.

Durability: The investment record spans inception through 2025, while distribution reach and recent organic inflows demonstrate an operating franchise. Its persistence depends on retaining investment talent and delivering competitive outcomes.

Risks: Competition spans fundraising, investment sourcing and retirement products. Private-equity results do not establish credit superiority; Athene's alternative-investment performance lagged its disclosed incentive benchmark, and Atlas experienced an underlying asset impairment.

Invalidation: Persistent benchmark-relative underperformance accompanied by declining organic fundraising or origination, lost distribution access, or material fee concessions needed to retain mandates would undermine the franchise advantage.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1858681/000185868126000013/apo-20251231.htm](https://www.sec.gov/Archives/edgar/data/1858681/000185868126000013/apo-20251231.htm) · 2026-02-25
- [https://www.sec.gov/Archives/edgar/data/1858681/000185868126000040/apo-20260630.htm](https://www.sec.gov/Archives/edgar/data/1858681/000185868126000040/apo-20260630.htm) · 2026-08-10
- [https://www.sec.gov/Archives/edgar/data/1858681/000119312526177321/d948913ddef14a.htm](https://www.sec.gov/Archives/edgar/data/1858681/000119312526177321/d948913ddef14a.htm) · 2026-04-24
- [https://www.sec.gov/Archives/edgar/data/1858681/000185868125000034/apo-20241231.htm](https://www.sec.gov/Archives/edgar/data/1858681/000185868125000034/apo-20241231.htm) · 2025-02-24
- [https://www.sec.gov/Archives/edgar/data/1858681/000185868124000031/apo-20231231.htm](https://www.sec.gov/Archives/edgar/data/1858681/000185868124000031/apo-20231231.htm) · 2024-02-27
- [https://www.sec.gov/Archives/edgar/data/1858681/000185868126000026/apo-20260331.htm](https://www.sec.gov/Archives/edgar/data/1858681/000185868126000026/apo-20260331.htm) · 2026-05-07

[JSON](https://beanvest.com/stock/apo/moat.json)